About the Authors

Thomas A. Ward

t.a.ward@leeds.ac.uk (TAW); stephen.durant@astrazeneca.com (STD)

Current address: Radiation Biology and Therapy Group, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Leeds, United Kingdom

Affiliations AstraZeneca, Innovative Medicines and Early Development Biotech Unit, Oncology Bioscience, Alderley Park, Macclesfield, Cheshire, United Kingdom, Department of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

Peter J. McHugh

Affiliation Department of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

Stephen T. Durant

t.a.ward@leeds.ac.uk (TAW); stephen.durant@astrazeneca.com (STD)

Affiliations AstraZeneca, Innovative Medicines and Early Development Biotech Unit, Oncology Bioscience, Alderley Park, Macclesfield, Cheshire, United Kingdom, AstraZeneca, Innovative Medicines and Early Development Biotech Unit, Oncology Bioscience, Little Chesterford, Cambridge, United Kingdom

Competing Interests

TAW was employed by AstraZeneca Pharmaceuticals under the Postdoctoral Researcher Program. STD is an employee of AstraZeneca Pharmaceuticals. AstraZeneca Pharmaceuticals provided financial assistance as declared in the ‘Financial Disclosure’. This does not alter our adherence to PLOS ONE policies on sharing data or materials.

Author Contributions

Conceptualization: TAW PJM STD. Data curation: TAW PJM STD. Formal analysis: TAW. Funding acquisition: PJM STD. Investigation: TAW. Methodology: TAW PJM STD. Project administration: TAW PJM STD. Resources: TAW PJM STD. Supervision: PJM STD. Validation: TAW PJM STD. Visualization: TAW. Writing – original draft: TAW. Writing – review & editing: TAW PJM STD.